Steps to Enroll in a Keytruda Clinical Trial
Search ClinicalTrials.gov, the main U.S. database for trials, using keywords like "pembrolizumab" (Keytruda's generic name) or "Keytruda." Filter by location, cancer type, phase, and recruitment status—over 1,800 active trials list pembrolizumab as of late 2024.[1] Merck, Keytruda's maker, runs many, often for cancers like melanoma, lung, or head/neck.
Check Merck's trial portal at merckclinicaltrials.com or keytruda.com for company-sponsored studies. It lists open trials with direct enrollment links.[2]
Eligibility Requirements for Keytruda Trials
Trials target specific patients: advanced cancers unresponsive to standard treatments, certain biomarkers (e.g., PD-L1 positive), or prior therapy failures. Age, performance status (ECOG score), organ function, and no conflicting meds are common criteria. Read the "Inclusion/Exclusion Criteria" on trial pages—e.g., NCT04553133 requires metastatic NSCLC with PD-L1 expression.[1]
How to Contact Sponsors and Sites
Submit inquiries via ClinicalTrials.gov's "Contact Information" for the lead sponsor (often Merck) or study sites. Expect screening: medical records review, eligibility quiz, then in-person consult. Sites like Mayo Clinic or MD Anderson handle many U.S. Keytruda trials.
For global options, use EU Clinical Trials Register or WHO's ICTRP.[3]
What Happens During Screening and Enrollment
If eligible, sign informed consent detailing risks (immune-related side effects like colitis, pneumonitis), benefits (potential access to Keytruda pre-approval), and procedures (scans, biopsies). Randomization may occur—some get Keytruda, others placebo/standard care. Trials last months to years with follow-ups.[1]
Keytruda Trial Timelines and Locations
Most recruit continuously; check "Status: Recruiting." U.S. hotspots: Texas (MD Anderson), New York (MSKCC), California. International sites in Europe, Asia. Start-to-enroll gap is weeks post-approval; phase 3 trials like KEYNOTE-671 enroll fastest.[1][2]
Costs, Travel Support, and Patient Assistance
Trials cover Keytruda, tests, and visits—no cost to you. Some offer travel stipends (e.g., Merck's programs up to $5,000). Uninsured? Trials don't require insurance. Post-trial, bridge to commercial Keytruda via Merck's patient support.[2]
Alternatives if You Don't Qualify
Ask your oncologist about expanded access (compassionate use) via Merck or FDA's Single Patient IND. Expanded access for Keytruda exists for refractory cases.[4] Biosimilars aren't available yet—Keytruda's main patents expire 2028 in U.S.[5]
[1]: ClinicalTrials.gov search for pembrolizumab
[2]: Merck Clinical Trials
[3]: EU Clinical Trials Register
[4]: FDA Expanded Access
[5]: DrugPatentWatch.com - Keytruda Patents